NASDAQ · Biotechnology

Prime Medicine, Inc. (PRME) Stock

$3.99 +11.45% NASDAQ: PRME Healthcare

Valuation

MetricValue
Price$3.99
Market Cap$720.66M
P/E Ratio-2.84
P/B Ratio13.91
P/S Ratio138.58
EPS (TTM)$-0.79
52-Week High$6.94
52-Week Low$2.67
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-188.27%
ROA-75.45%
ROCE-90.42%
Gross Margin-10.83%
Operating Margin-51.22%
Net Margin-49.18%
Debt/Equity2.83
Current Ratio4.89

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$3.0M$5.0M
Operating Profit$-84.0M$-117.0M$-205.0M$-202.0M$-208.0M
Net Profit$-165.0M$-122.0M$-198.0M$-196.0M$-201.0M
EPS$-1.92$-1.46$-2.18$-1.65$-1.35
Op Margin———-6787.4%-4498.1%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$302.0M$360.0M$194.0M$298.0M$343.0M
Total Liabilities$62.0M$44.0M$61.0M$144.0M$222.0M
Cash$185.0M$188.0M$42.0M$182.0M$63.0M
Borrowings$10.0M$29.0M$14.0M$41.0M$116.0M

Latest News

Bank of America Securities Maintains Buy Rating for Beam Therapeutics (BEAM) Insider Monkey · Jul 15, 2026 Prime Medicine (PRME) Reaches Positive Resolution to Arbitration with Beam Therapeutics Insider Monkey · Jul 15, 2026 Cathie Wood Dumps AMD, Doubles Down on Meta Stock GuruFocus.com · Jul 10, 2026 Beam Therapeutics (BEAM) Faces New AATD Rival PM647 Ruling What Does It Signal Strategically? Simply Wall St. · Jul 9, 2026 Gene Editors, Including Powerhouse Beam Therapeutics, Diverge On Legal Battle Investor's Business Daily · Jul 8, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-34.0M$-132.0M$-165.0M$-123.0M$-163.0M
Investing Cash Flow$-78.0M$-63.0M$10.0M$61.0M$-113.0M
Financing Cash Flow$-1.0M$-4.0M$0$26.0M$12.0M
Net Cash Flow$162.0M$3.0M$-146.0M$141.0M$-120.0M
Free Cash Flow$-38.0M$-148.0M$-174.0M$-130.0M$-167.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.07
EV / EBITDA-3.49
FCF Yield-27.79%
Quick Ratio3.05
Interest Coverage0.00
Return 1Y-35.99%
Return 3Y-79.60%
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BEAMBeam Therapeutics Inc. $25.70 +4.47% -29.88 $2.64B 0.00%
CRBUCaribou Biosciences, Inc. $0.46 -4.36% -1.13 $45.64M 0.00%
CRSPCRISPR Therapeutics AG $53.39 +5.85% -11.62 $5.15B 0.00%
DSGNDesign Therapeutics, Inc. $11.65 +1.39% -10.46 $727.62M 0.00%
EDITEditas Medicine, Inc. $2.90 +2.11% -3.50 $445.04M 0.00%

About Prime Medicine, Inc.

Prime Medicine, Inc. is led by CEO Allan Reine, employs 214 people, headquartered in US, publicly traded since 2022.

Prime Medicine, Inc. (PRME) stock trades at $3.99 with a market capitalization of $720.66M. The stock is valued at a price-to-earnings (P/E) ratio of -2.84, price-to-book of 13.91, price-to-sales of 138.58. Over the past 52 weeks the stock has ranged between $2.67 and $6.94, and currently trades 42.5% below its 52-week high.

On profitability, Prime Medicine, Inc. generates a return on equity (ROE) of -188.27%, return on capital employed of -90.42%, an operating margin of -51.22%, a net profit margin of -49.18%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides